Kathleen Reape BA, MD

Kathy Reape is the Chief Medical Officer of Spark Therapeutics and oversees clinical, pharmacovigilance and medical affairs activities. With more than 18 years of pharmaceutical industry experience in clinical drug development, Kathy has overseen numerous clinical trials and had a hands-on role in the approvals of more than two dozen products including small molecules, biologics, biosimilars, and devices spanning a wide range of therapeutic areas. Prior to joining Spark, Kathy was the president of Ark Medical Consulting LLC where she provided pharmaceutical and medical consulting and the Senior Vice President, Head of Clinical Development, Global Brands R&D for Allergan, plc where she led the Clinical Development function for the entire brand R&D portfolio, including projects in ophthalmology, cardiovascular, gastrointestinal, anti-infectives, respiratory, women’s health, urology, dermatology/aesthetics, and central nervous system (CNS). She also oversaw all development work related to Allergan’s onabotulinumtoxinA (BOTOX®). Kathy has also held leadership positions at Teva Pharmaceuticals, Duramed Research and Wyeth Pharmaceuticals. She received her M.D. from the University of Pennsylvania and completed her internship and residency at the University of Florida and the University of Medicine and Dentistry of New Jersey.